title: Lack of significant activity of 2'-deoxycoformycin alone or in combination with adenine arabinoside in relapsed childhood acute lymphoblastic leukemia. A randomized phase II trial from the Childrens Cancer Study Group.
abstract: Forty-nine children with recurrent acute lymphoblastic leukemia (ALL) were entered into a randomized Phase II trial evaluating 2'-deoxycoformycin (dCF) alone or in combination with adenine arabinoside (ara-A). 2'-Deoxycoformycin is an inhibitor of adenosine deaminase (ADA), an enzyme found in relatively high amounts in malignant lymphoid cells. Ara-A inhibits DNA polymerase and DNA synthesis. Because its efficacy in vivo as an anticancer agent is limited by its rapid inactivation by ADA, ara-A was combined with dCF to produce cytoreductive levels of ara-A. Twenty-four patients were assigned to receive dCF alone and 25 to receive the combination. No patient responded to dCF alone, and one patient developed a complete remission after treatment with the combination. The toxicity of dCF alone was minimal, except for one patient who became obtunded on day 5 following the first cycle of therapy. In contrast, five patients developed severe toxicity with the combination, including renal failure (three patients), hepatic failure (three patients), and neurologic toxicity (two patients). These results indicate that, at the doses and schedule used in this study, the combination of dCF and ara-A has significant toxicity and minimal activity against recurrent ALL in children.
authors.affiliation: Mayo Clinic, Rochester, Minnesota.
authors.forename: J S
authors.initials: JS
authors.lastname: Miser
authors.forename: J
authors.initials: J
authors.lastname: Roloff
authors.forename: J
authors.initials: J
authors.lastname: Blatt
authors.forename: G H
authors.initials: GH
authors.lastname: Reaman
authors.forename: M D
authors.initials: MD
authors.lastname: Krailo
authors.forename: G D
authors.initials: GD
authors.lastname: Hammond
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002648:Child; D004357:Drug Synergism; D006801:Humans; D016130:Immunophenotyping; D015649:Pentostatin / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000276:immunology; D012008:Recurrence; D014740:Vidarabine / Q000008:administration & dosage
chemical_list: D015649:Pentostatin; D014740:Vidarabine